Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/s41409-021-01560-y | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The role of daratumumab in complications post-allogeneic hematopoietic stem cell transplantation: a single-center prospective study on PRCA and AIHA.
Bone Marrow Transplant
November 2024
Sezione di Ematologia, Dipartimento di Scienze Radiologiche ed Ematologiche, Università Cattolica del Sacro Cuore, Rome, Italy.
Pure red cell aplasia (PRCA) and autoimmune hemolytic anemia (AIHA) post-hematopoietic stem cell transplantation (HSCT) are an unmet medical need with no established standard of care, significantly affecting the patient quality of life and posing a challenge for clinicians. The anti-CD38 IgG-kappa Daratumumab appears to be a safe and efficace treatment compared to prior drugs. Our study is a prospective monocentric investigation assessing the use of daratumumab in these complications following allo-HSCT.
View Article and Find Full Text PDFDaratumumab and Eltrombopag for Pure Red Cell Aplasia Following ABO-Incompatible Allogeneic Hematopoietic Stem Cell Transplant for Acute Lymphoblastic Leukemia.
Turk J Haematol
December 2024
University of Health Sciences Türkiye, Ankara Bilkent City Hospital, Clinic of Hematology, Ankara, Türkiye
Novel Drug Combinations and Donor Lymphocyte Infusions Allow Prolonged Disease Control in Multiple Myeloma Patients Relapsing after Allogeneic Transplantation.
Transplant Cell Ther
November 2024
Azienda Sanitaria Universitaria Friuli Centrale, DMED, University of Udine, Udine, Italy.
Article Synopsis
- Allogeneic stem cell transplantation (allo-SCT) offers curative potential for multiple myeloma patients but is effective in only a minority, with some patients experiencing long-term survival after relapse thanks to a combination of antimyeloma drugs and donor T cells.
- A study evaluating 242 multiple myeloma patients who underwent allo-SCT revealed a median overall survival of 39.4 months and highlighted factors like older age and previous therapies that predict shorter survival outcomes.
- Among 118 relapsed patients, various treatments were employed, with a significant portion receiving multiple lines of salvage therapy, including chemotherapy and immunomodulating agents, demonstrating a diverse treatment approach post-relapse.
Daratumumab in the Management of Red Cell Aplasia Following Allogeneic Hematopoietic Stem Cell Transplantation.
Eur J Haematol
November 2024
Hans Messner Allogeneic Blood and Marrow Transplant Program, Division of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Canada.
Pure red cell aplasia (PRCA) is a rare but significant complication following major ABO-incompatible allogeneic hematopoietic stem cell transplantation (HSCT). The persistence of recipient B lymphocytes producing anti-donor isohemagglutinins leads to reticulocytopenia and anemia, often resulting in transfusion dependence. Current treatment options for post-HSCT PRCA are limited and frequently yield suboptimal responses, complicating patient management.
View Article and Find Full Text PDFIsatuximab for Delayed Red Cell Engraftment after Allogeneic Hematopoietic Cell Transplantation.
Case Rep Hematol
August 2024
Department of Medicine Adult Bone Marrow Transplantation Service Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Isatuximab is an IgG1-derived monoclonal antibody against CD38 approved for the treatment of adult patients with multiple myeloma. Here we describe the successful treatment of a therapy-refractory pure red cell aplasia case following ABO-mismatched allogeneic stem cell transplantation with isatuximab. Our patient was a 75-year-old female with acute myeloid leukemia who received an HLA-B antigen mismatched, unrelated peripheral blood stem cell transplant with a major ABO incompatibility (blood group A+ in the donor and blood group O+ in the recipient).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!